TNGX — Tango Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $163.24m
- -$94.67m
- $42.07m
Annual cashflow statement for Tango Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.123 | -58.2 | -108 | -102 | -130 |
| Depreciation | |||||
| Non-Cash Items | -0.065 | 9.16 | 16 | 19.3 | 28 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.139 | -11.3 | -18.5 | -38 | -31.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.327 | -59.5 | -109 | -118 | -132 |
| Capital Expenditures | — | -1.84 | -7.69 | -1.53 | -0.754 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -167 | -182 | 34.1 | 43 | 86.9 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -167 | -183 | 26.4 | 41.4 | 86.1 |
| Financing Cash Flow Items | -3.72 | 326 | -0.008 | 0.448 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 168 | 357 | 1.61 | 82.4 | 47.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.31 | 114 | -81.1 | 5.85 | 2.29 |